Impact of Ageing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Impact of Ageing
Despite the fact that Europe's population is ageing rapidly, the region is astonishingly still underprepared for dealing with the health-related effect of this demographic trend. A major challenge for governments in the EU is meeting rising demand for healthcare whilst tailoring the systems to needs of the elderly.


Pharmaceutical Technology Europe
Volume 23, Issue 12

Outlook

Europe faces serious challenges in sustaining its healthcare systems to deliver high quality services to the elderly. Initiatives are being launched at a European level and have received high profile backing from the EC, the EMA and key geriatricians. Such an approach has led to improvements in addressing the gaps seen in paediatric medicine and is seen as a potential model for making improvements with respect to the elderly. Sadly, the ongoing economic difficulties in Europe may hinder investment in additional healthcare services for the elderly as politicians look to implement cutbacks. However, the elderly also represent a growing proportion of the voting population and will therefore not accept their long-term healthcare needs being ignored. For the pharmaceutical industry the demographic trends present opportunities to launch new therapies in these disease areas.

References

1. EC, "Elderly" (2011). http://ec.europa.eu/, accessed Nov. 11, 2011.

2. D.M. Qato et al., J. Gerontol. B. Psychol. Sci. Soc. Sci. 64 Suppl. 1, i86–93 (2009).

3. P.A. Rochon et al., "Drug prescribing for older adults," UpToDate (2011). http://www.uptodate.com/, accessed Nov. 11, 2011.

4. EC, "European Innovation Partnership agrees on actions to turn ageing into an opportunity," Press Release (2011). http://ec.europa.eu/, accessed Nov. 11, 2011.

5. BBC News, "Eurozone's growth has stalled, says EU," (2011). http://www.bbc.co.uk/, accessed Nov. 11, 2011.

6. PREDICT, "Increasing the participation of the elderly in clinical trials," (2011). http://www.predicteu.org/, accessed Nov. 11, 2011.

7. A. Cherubini, Arch Intern Med. 171(6), 550–556 (2011).

8. EMA, "EMA workshop on medicines for older people," (2011). http://www.ema.europa.eu/, accessed Nov. 11, 2011.

9. Decision Resources, "The Alzheimer's disease drug market will nearly triple over the next ten years," (2011). http://decisionresources.com/, accessed Nov. 11, 2011.

10. A. Palmer, "It's not Nice… but the alternative is worse." (Daily Telegraph, 2007). http://www.telegraph.co.uk/, accessed Nov. 11, 2011.

11. Inpharm, "Pfizer has signed a five-year research pact with US healthcare insurer Humana," (2011). http://www.inpharm.com/, accessed Nov. 11, 2011.

12. G. Forrer, "Treating chronic disease could help forestall onset of Alzheimer's disease," (PhRMA, 2011). http://www.phrma.org/, accessed Nov. 11, 2011.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here